Unicycive Therapeutics, Inc.
UNCYHealthcare|Biotechnology|US
$3.55
+0.07 (+2.01%)
DCF Value
$1.81
Tangible Book / Share
$1.98
Cash / Share
$2.28
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06218290 A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis | Chronic Kidney Disease Requiring Chronic Dialysis | P2 | Completed | 106 | Open-label | Oxylanthanum Carbonate |